You are here: Industry Insights > Celgene

News List

Is Celgene Considering Going Private? biospace
March 16, 2018
Despite a deep pipeline and a market cap of $69.4 billion, Celgene shares are down 12 percent year to date.
Celgene strikes $101m partnership in oncology, neurodegenerative and inflammatory pharmafile
March 06, 2018
Celgene has signed a new multi-year partnership agreement with biotech company Vividion Therapeutics
Celgene to tackle ‘undruggable’ targets with Vividion pharmaphorum
March 06, 2018
Celgene has signed a deal with Vividion Therapeutics to develop drugs for oncology, inflammatory, and neurodegenerative diseases.
Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc. biospace
March 06, 2018
Celgene Corporation (NASDAQ: CELG) announced today that its offer to acquire Juno Therapeutics, Inc
Vividion Therapeutics Snags $101M from Celgene biospace
March 06, 2018
Celgene continues to make friends in the biotech industry.
Ballsy Celgene Continues to Tread Carefully Into Neurosciences biospace
January 29, 2018
Two years ago during a lunch with a group of reporters at the J.P. Morgan confab, then Celgene CEO (now executive chairman) Bob Hugin got my attention with a comment on the importance of neurosciences in the pipeline.
Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 fiercebiotech
January 23, 2018
Celgene has agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal that instantly makes it a big cheese in this emerging therapeutic category.
Juno Explodes on Celgene Takeover Rumors biospace
January 18, 2018
Rumors that Celgene Corporation is in talks to acquire Juno Therapeutics has caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
Celgene to Buy Impact Biomedicines for up to $7B contractpharma
January 15, 2018
Celgene Corporation and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera.
Celgene Scoops Up San Diego Biotech in $7B Deal biospace
January 09, 2018
Celgene began the week of the J.P. Morgan Healthcare Conference with a $7 billion announcement. The company said it will acquire San Diego-based Impact Biomedicines and its JAK inhibitor progra

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page